ClinicalTrials.gg
RecruitingNCT07112053Updated Nov 2, 2026

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

A Phase 2 interventional study of CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine and Capecitabine in Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma and Metastatic Hormone Receptor-Positive Breast Carcinoma, sponsored by University of Washington. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University of Washington · Phase 2, Interventional, and Treatment

How we know · 15 judgments

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Breast Neoplasms by University of Washington — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · University of Washington.

Planned enrollment
22nd of 56
40 · median 35
Started
2025
with 2 others
Phase 2
23 of 64
5 open now
Primary completion
2028-07
later than 8 of 10 live
Registered
62nd of 64
by date

Among the 64 studies in Breast Neoplasms by University of Washington, this one is the 22nd largest by planned enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2025, is one of 23 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 62nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 64 studies in Breast Neoplasms by University of Washington are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Breast Neoplasms by University of Washington, or all of them as a file.
02

Study summary

This phase II trial studies how well a vaccine, STEMVAC, works in combination with standard endocrine-based therapy (ET) with a CDK4/6 targeted drug therapy, or with the chemotherapy drug capecitabine, in treating patients with hormone receptor (HR)-positive, HER2-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). STEMVAC is designed to target proteins that cancer cells use when they become more aggressive and start to spread, and it is believed to work by boosting the immune system to recognize and destroy the invader tumor cells that are causing the disease. Standard ET is treatment that adds, blocks, or removes hormones in order to slow or stop the growth of cancer. Standard CDK4/6 inhibitors, including abemaciclib, may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Capecitabine is in a class of medications called antimetabolites. It is taken up by tumor cells and breaks down into fluorouracil, a substance that kills tumor cells. Giving STEMVAC in combination with standard ET or chemotherapy may be an effective treatment for metastatic HR positive, HER2 negative breast cancer.

Read the detailed description

OUTLINE: Patients with ET-sensitive disease are assigned to Cohort 1, while patients with ET-resistant disease are assigned to Cohort 2.

COHORT 1: After completion of 2 cycles of standard of care (SOC) ET + CDK4/6 inhibitor (CDK4/6i) therapy or abemaciclib alone, patients receive STEMVAC intradermally (ID) on the following schedule: 1) Three "priming" doses every 28 days; 2) Two "booster" doses at 6 and 9 months after "priming" dose #1; and 3) Additional "booster" doses every 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo image-guided biopsies for research purposes, as well as collection of blood samples and computed tomography (CT) or positron emission tomography (PET) scans throughout the trial.

COHORT 2: After completion of 1 cycle of SOC capecitabine treatment, patients receive STEMVAC ID on the following schedule: 1) Three "priming" doses every 28 days; 2) Two "booster" doses at 6 and 9 months after "priming" dose #1; and 3) Additional "booster" doses every 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo image-guided biopsies for research purposes, collection of blood samples, and fluoroestradiol (FES) positron emission tomography (PET) scans, as well as CT or PET scans throughout the trial.

After completion of study treatment, patients are followed every 6 months for 3 years.

03

Conditions studied

  • Anatomic Stage IV Breast Cancer AJCC v8
  • Metastatic HER2-Negative Breast Carcinoma
  • Metastatic Hormone Receptor-Positive Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be at least ≥ 18 years of age
  • confirmed hormone receptor positive breast cancer: Tumors that are positive for estrogen receptor (ER) and/or progesterone receptor (PR)
  • -negative or HER2-low will be included and defined as:

    • 0-1+ HER2 expression by immunohistochemistry (IHC) OR
    • Fluorescence in situ hybridization (FISH) negative OR
    • HER2 2+ and FISH negative
    • HER2 low per standard of care in breast cancer
  • Patients should be receiving the following therapies to be eligible for the study:

    • Cohort 1: First or of endocrine therapy in the metastatic setting, in combination with a CDK4/6 inhibitor. Patients must have completed at least 2 cycles of CDK4/6 inhibitor. Patients who have stopped endocrine therapy for intolerance but remain on abemaciclib monotherapy will be considered for enrollment at the PI's discretion
    • Cohort 2: Progressed on endocrine-based therapies and after completion of at least 1 cycle of capecitabine
  • Subjects with (ECOG) Performance Status Score of 0 or 1
  • Willing to undergo up to two serial while on study
  • Have at least 1 site of disease confirmed by the treating oncologist that could be biopsied during treatment
  • White blood cell (WBC) ≥ 2000/mm\^3 (within 28 days of receiving the study vaccine)
  • Lymphocyte count ≥ 500/mm\^3 (within 28 days of receiving the study vaccine)
  • (ANC) ≥ 800/µL (within 28 days of receiving the study vaccine)
  • ≥ 75,000/µL (within 28 days of receiving the study vaccine)
  • Total ≤ 1.5 x institutional (ULN), except patients with Gilbert's syndrome in whom total bilirubin must be ≤ 3.0 mg/dL (within 28 days of receiving the study vaccine)
  • (AST)/alanine aminotransferase (ALT) ≤ 3 x institutional upper limit of normal (ULN) (within 28 days of receiving the study vaccine)
  • Creatinine ≤ 2.0 mg/dL or > 30 mL/min (within 28 days of receiving the study vaccine)
  • Patients of must agree to use dual methods of and have a negative urine pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or . Effective methods of contraception must be used throughout the study and until the end of treatment on study
  • Must have recovered from major infections and/or surgical procedures; and in the opinion of the investigator, not have any significant active concurrent medical illnesses or condition precluding protocol treatment

Exclusion criteria

Exclusion Criteria:

  • Patients with any of the following cardiac conditions:

    • Symptomatic restrictive cardiomyopathy
    • Dilated cardiomyopathy
    • Unstable angina within 4 months prior to enrollment
    • functional class III-IV heart failure on active treatment
    • Symptomatic pericardial effusion
    • Uncontrolled hypertension
    • Uncontrolled cardiac arrhythmias
  • Patients with any disease/comorbidity that require chronic or
  • A non-breast requiring radiation or systemic therapy within last 5 years
  • Known reaction to the granulocyte-macrophage colony-stimulating factor (GM-CSF) adjuvant; any known to GM-CSF
  • Pregnant or breast feeding
  • Known history of (HIV) infection, (e.g., hepatitis B virus surface antigen [HBsAg] reactive), or (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)
  • Major surgery within the 4 weeks prior to initiation of study vaccine
  • Current use of immunosuppressive agents or systemic corticosteroids. Topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption) are allowed. Patients who have received systemic corticosteroids ≤ 30 days prior to starting study drug will be excluded
  • Patient is currently enrolled in any other clinical protocol or trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug

    • NOTE: Biomarker or tissue collection or any other non-interventional clinical trial enrollment is allowed
  • Must be 14 days between a non-study vaccine and any STEMVAC vaccination

    • NOTE: The minimum of 14 days does not apply to the tetanus and diphtheria (Td) vaccine
  • Any condition that may interfere with the patient's participation in the study per treating oncologist
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort 1 (STEMVAC, ET + CDK4/6i)

    After completion of 2 cycles of SOC ET + CDK4/6i therapy or abemaciclib alone, patients receive STEMVAC ID on the following schedule: 1) Three "priming" doses every 28 days; 2) Two "booster" doses at 6 and 9 months after "priming" dose #3; and 3) Additional "booster" doses every 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo image-guided biopsies, as well as collection of blood samples and CT or PET scans throughout the trial.

    Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine · Procedure: Computed Tomography · Drug: Cyclin-Dependent Kinase 4 Inhibitor · Drug: Cyclin-Dependent Kinase 6 Inhibitor · Drug: Hormone Therapy · Procedure: Positron Emission Tomography · Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Abemaciclib

  • Experimental
    Cohort 2 (STEMVAC, capecitabine)

    After completion of 1 cycle of SOC capecitabine treatment, patients receive STEMVAC ID on the following schedule: 1) Three "priming" doses every 28 days; 2) Two "booster" doses at 6 and 9 months after "priming" dose #3; and 3) Additional "booster" doses every 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo image-guided biopsies, collection of blood samples, and FES PET scans, as well as CT or PET scans throughout the trial.

    Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine · Drug: Capecitabine · Procedure: Computed Tomography · Drug: F-18 16 Alpha-Fluoroestradiol · Procedure: Positron Emission Tomography · Procedure: Biopsy Procedure · Procedure: Biospecimen Collection

Interventions

  • BiologicalCD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

    Drug page: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA VaccineStudies of CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA VaccineCD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given ID

    Also known as: STEMVAC, STEMVAC Th1 Polyepitope Plasmid-based Vaccine, CD105/Yb-1/SOX2/CDH3/MDM2 Plasmid Vaccine

  • Given SOC capecitabine

    Also known as: Ro 09-1978/000, Xeloda

  • ProcedureComputed Tomography

    Undergo CT or ultrasound-guided biopsies

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography

  • DrugCyclin-Dependent Kinase 4 Inhibitor

    Given SOC CDK4/6i

    Also known as: CDK4 Inhibitor

  • DrugCyclin-Dependent Kinase 6 Inhibitor

    Given SOC CDK4/6i

    Also known as: CDK6 Inhibitor

  • DrugFluoroestradiol f-18Studies of Fluoroestradiol f-18Fluoroestradiol f-18 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Undergo FES PET

    Also known as: 16 alpha-fluroestradiol-17 beta, F-18 FES, FES, Fluorine-18 16 alpha-fluoroestradiol, Fluoroestradiol F-18

  • DrugHormone Therapy

    Given SOC ET

    Also known as: Chemotherapy-Hormones/Steroids, Endocrine Therapy, Hormonal, Hormonal Therapy, hormone treatment, Hormones

  • ProcedurePositron Emission Tomography

    Undergo PET or FES PET

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • ProcedureBiopsy Procedure

    Undergo image-guided biopsies

    Also known as: Biopsy, BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection

  • Given SOC abemaciclib

    Also known as: LY 2835219, LY-2835219, LY2835219, Verzenio

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Safety and systemic toxicity will be determined by chemical and clinical parameters evaluated at various time points. Toxicity grading will be evaluated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 6.0 and monitoring of AEs will be done per Food and Drug Administration and NCI guidelines. The type and grade of toxicities noted during the immunization regimen will be summarized. The duration of toxicities will also be summarized using descriptive statistics such as mean and standard deviation. All AEs noted by the investigator will be tabulated according to the affected body system. The frequency and severity of adverse events will be summarized with a proportion and a 95% confidence interval (CI).

    Time frame: Up to 3 years after completion of study treatment

  2. Incidence of immunogenicity

    Will be defined as the sum of the interferon gamma enzyme-linked immunosorbent spot of all STEMVAC antigens on blood samples collected pre-vaccine as compared to 1-month post dose #3 of the STEMVAC vaccine and again after 2 booster doses of STEMVAC vaccine. Both incidence and magnitude will be assessed. Immune responses will be summarized with mean and standard deviation or median and range (if skewness is observed) over time, the change over time will be summarized with graphs, and also analyzed using linear mixed-effects regression models with normalizing transformation if necessary.

    Time frame: Pre-vaccine up to after 2 booster doses of STEMVAC vaccine (Up to 40 weeks)

Secondary outcomes

  1. Progression-free survival (PFS)

    Will be analyzed using the Kaplan-Meier method. Kaplan-Meier estimates of the survival function with 95% CIs at specific time points (using Greenwood's formula for the standard error) will be computed.

    Time frame: From the start of treatment to the worsening of cancer as determined by primary treating oncologist or death whichever occurs first, assessed up to 3 years after completion of study treatment

  2. Circulating tumor DNA (ctDNA)

    Will evaluate persistence and level of ctDNA over time in peripheral blood with addition of STEMVAC at baseline, after completion of priming monthly doses, at booster vaccines, and at progression (end of study). Linear mixed-effects regression models with normalizing transformation (if necessary) will be employed to evaluate changes in ctDNA levels over time. Paired t test or Wilcoxon signed rank tests will be applied for pairwise comparisons (depending on the distribution) between time points.

    Time frame: Up to 3 years after completion of study treatment

  3. Elimination of cancer cells associated with epithelial to mesenchymal transformation (EMT)

    Will determine whether STEMVAC immunization in addition to either endocrine therapy plus a CDK4/6 inhibitor or capecitabine results in elimination of cancer cells associated with EMT, as EMT proteins are targeted by this vaccine. Will determine EMT signature by gene expression profiling in baseline tumor (previously collected tumor biopsy) and compare with post-STEMVAC tumor biopsy. Gene expression profiles from biopsies before and after vaccination will be compared using paired t test or Wilcoxon signed-rank test (depending on the distribution) to determine if vaccination modulates the EMT gene signature in the tumor. Differential gene expression analysis or linear models will be used to analyze individual EMT gene expression levels.

    Time frame: Up to 3 years after completion of study treatment

07

Study locations

1 of 1 sites recruiting
  • Fred Hutch/University of Washington Cancer Consortium
    Seattle, Washington 98109, United States
    Recruiting
    • Research Coordinator(s) · Contactcvitrial@uw.edu · 866-932-8588
    • Natasha Hunter, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2028, 32 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 32 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Aug 8, 2025
StartActual
Nov 17, 2025
Primary completionEst.
Jul 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07112053
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Nov 17, 2025
Primary completion
Jul 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Research Coordinator(s)
Contact
cvitrial@uw.edu
1-866-932-8588
Natasha Hunter, MD
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion